{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:48:25Z","timestamp":1794001705469,"version":"4.8.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:p>Type 2 diabetic kidney disease (DKD) is the most common cause of CKD and ESRD worldwide, and carries with it enormous human and societal costs. The goal of this review is to provide an update on the diagnosis and management of DKD based on a comprehensive review of the medical literature. Topics addressed include the evolving presentation of DKD, clinical differentiation of DKD from non-DKD, a state-of-the-art evaluation of current treatment strategies, and promising emerging treatments. It is expected that the review will help clinicians to diagnose and manage patients with DKD.<\/jats:p>","DOI":"10.2215\/cjn.11111016","type":"journal-article","created":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T20:25:27Z","timestamp":1489091127000},"page":"1366-1373","source":"Crossref","is-referenced-by-count":305,"title":["Diagnosis and Management of Type 2 Diabetic Kidney Disease"],"prefix":"10.2215","volume":"12","author":[{"given":"Simit M.","family":"Doshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allon N.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,3,9]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/1756-0500-7-415","article-title":"Chronic kidney disease in US adults with type 2 diabetes: An updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging","volume":"7","author":"Bailey","year":"2014","journal-title":"BMC Res Notes"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1053\/j.ajkd.2014.08.001","article-title":"Diabetic kidney disease: A report from an ADA Consensus Conference","volume":"64","author":"Tuttle","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2337\/dc13-1870","article-title":"Microalbuminuria as a risk predictor in diabetes: The continuing saga","volume":"37","author":"Bakris","year":"2014","journal-title":"Diabetes Care"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","article-title":"Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)","volume":"63","author":"Adler","year":"2003","journal-title":"Kidney Int"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000333249","article-title":"Renal dysfunction in the presence of normoalbuminuria in type 2 diabetes: Results from the DEMAND study","volume":"2","author":"Dwyer","year":"2012","journal-title":"Cardiorenal Med"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1001\/jama.289.24.3273","article-title":"Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus","volume":"289","author":"Kramer","year":"2003","journal-title":"JAMA"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1097\/HJH.0b013e3283495cd6","article-title":"Clinical significance of nonalbuminuric renal impairment in type 2 diabetes","volume":"29","author":"Penno","year":"2011","journal-title":"J Hypertens"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.2337\/dc08-2186","article-title":"Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11)","volume":"32","author":"Thomas","year":"2009","journal-title":"Diabetes Care"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.diabres.2011.01.017","article-title":"Renal outcomes in patients with type 2 diabetes with or without coexisting non-diabetic renal disease","volume":"92","author":"Chang","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000102598","article-title":"Prevalence of nondiabetic renal disease in diabetic patients","volume":"27","author":"Pham","year":"2007","journal-title":"Am J Nephrol"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.diabres.2005.02.009","article-title":"Clinical features of non-diabetic renal diseases in patients with type 2 diabetes","volume":"69","author":"Tone","year":"2005","journal-title":"Diabetes Res Clin Pract"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2215\/CJN.02510213","article-title":"The modern spectrum of renal biopsy findings in patients with diabetes","volume":"8","author":"Sharma","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"Suppl 2","key":"B15-20230813","first-page":"S12","article-title":"KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease","volume":"49","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"B16-20230813","first-page":"S4","article-title":"Standards of medical care in diabetes-2016: Summary of revisions","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","year":"1998","journal-title":"BMJ"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/ki.2011.415","article-title":"Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients","volume":"81","author":"Ismail-Beigi","year":"2012","journal-title":"Kidney Int"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1681\/ASN.2004090763","article-title":"Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial","volume":"16","author":"Berl","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N Engl J Med"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.2215\/CJN.03470316","article-title":"Incidence, severity, and outcomes of AKI associated with dual renin-angiotensin system blockade","volume":"11","author":"Palevsky","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S2213-8587(15)00469-6","article-title":"Renal outcomes with aliskiren in patients with type 2 diabetes: A prespecified secondary analysis of the ALTITUDE randomised controlled trial","volume":"4","author":"Heerspink","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"B31-20230813","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/ki.2012.401","article-title":"Intensive glucose control improves kidney outcomes in patients with type 2 diabetes","volume":"83","author":"Perkovic","year":"2013","journal-title":"Kidney Int"},{"key":"B32-20230813","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"B34-20230813","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1007\/s00125-016-4017-1","article-title":"Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment","volume":"59","author":"Fioretto","year":"2016","journal-title":"Diabetologia"},{"key":"B35-20230813","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"B37-20230813","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.2337\/dc13-0323","article-title":"Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction","volume":"36","author":"Groop","year":"2013","journal-title":"Diabetes Care"},{"key":"B38-20230813","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.2337\/dc16-1415","article-title":"Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: Outcomes from TECOS","volume":"39","author":"Cornel","year":"2016","journal-title":"Diabetes Care"},{"key":"B39-20230813","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S2213-8587(14)70156-1","article-title":"Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: A secondary analysis of the Look AHEAD randomised clinical trial","volume":"2","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B41-20230813","doi-asserted-by":"crossref","first-page":"528","DOI":"10.2215\/CJN.07670715","article-title":"Is bariatric surgery an effective treatment for type II diabetic kidney disease?","volume":"11","author":"Friedman","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B42-20230813","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.kint.2016.02.039","article-title":"Bariatric surgery is associated with improvement in kidney outcomes","volume":"90","author":"Chang","year":"2016","journal-title":"Kidney Int"},{"key":"B43-20230813","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1681\/ASN.2006030208","article-title":"Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism","volume":"18","author":"Sasser","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B44-20230813","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1681\/ASN.2013080830","article-title":"The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy","volume":"25","author":"de Zeeuw","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B45-20230813","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1177\/2047487315598709","article-title":"Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers","volume":"23","author":"Schievink","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"B46-20230813","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201708000-00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:36:38Z","timestamp":1786368998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201708000-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,9]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.11111016","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,9]]}}}